MARKET

PULM

PULM

Pulmatrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8000
+0.0151
+1.92%
Closed 16:00 11/21 EST
OPEN
0.8189
PREV CLOSE
0.7849
HIGH
0.8189
LOW
0.7500
VOLUME
228.09K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
0.6103
MARKET CAP
16.00M
P/E (TTM)
-0.3644
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PULM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PULM News

  • Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors
  • PR Newswire.11/04 14:15
  • Pulmatrix EPS beats by $0.16
  • seekingalpha.11/01 18:24
  • Pulmatrix Reports Q3 2019 Results
  • PR Newswire.11/01 14:00
  • Pulmatrix Q3 EPS $(0.18) Down From $(0.1) YoY, Sales $1.406M
  • Benzinga.11/01 13:07

More

Industry

Biotechnology & Medical Research
-0.11%
Pharmaceuticals & Medical Research
+0.43%

Hot Stocks

Name
Price
%Change

About PULM

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.
More

Webull offers Pulmatrix Inc (PULM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.